Corporate News Update – Frankfurt Stock Exchange, September 28 2026

Market Overview

On Friday, September 28 2026, the Frankfurt exchange registered modest gains in both the broader DAX and the LUS‑DAX indices. At mid‑afternoon, the DAX closed slightly higher, while the LUS‑DAX remained essentially flat, a pattern that reflected the prevailing cautious sentiment among investors. The day’s trading volume underscored the continued resilience of several key German stocks, particularly those operating in the health‑tech and pharmaceutical sectors.

Performance of Key Constituents

  • Fresenius SE emerged as the most prominent performer in both indices, posting a moderate increase that helped lift the overall market mood. Fresenius’ steady upward trajectory aligns with its recent operational milestones, including the successful roll‑out of its new dialysis technology platform and the expansion of its outpatient care network in central Europe.

  • Siemens Healthineers and Merck KGaA also reported gains, reinforcing investor confidence in Germany’s health‑tech and pharmaceutical industries. Siemens Healthineers’ performance is attributable to a strong earnings release, where its digital imaging and laboratory diagnostics segments exceeded revenue forecasts by 8 %. Merck’s share rise follows the announcement of a Phase III trial success for its novel oncology agent, which achieved a statistically significant 12 % improvement in progression‑free survival versus the standard of care.

  • SAP SE and Infineon Technologies AG recorded modest declines. SAP’s share price fell 1.3 % after a slight under‑performance in its cloud‑services segment, while Infineon’s 0.9 % dip reflected broader semiconductor‑sector volatility driven by supply‑chain constraints.

Broader Market Context

Over the past twelve months, both the DAX and the LUS‑DAX have climbed several percentage points, reaching new annual highs earlier in the year. The market capitalization of the index constituents remains robust, with large-cap names such as SAP SE retaining the highest market values. This backdrop provides a solid foundation for the observed gains, while also highlighting the importance of sector‑specific dynamics.

From a fundamental perspective, analysts highlighted two key valuation metrics:

  • Volkswagen AG exhibited the lowest price‑earnings (P/E) ratio among the index constituents, suggesting that its valuation may be undervalued relative to its earnings potential. The company’s recent shift toward electrification and autonomous driving technologies is expected to drive long‑term revenue growth.

  • Mercedes‑Benz Group AG was identified as offering the most attractive dividend yield for the year. The automaker’s dividend policy, coupled with its strong cash‑flow generation, positions it as a compelling option for income‑oriented institutional investors.

Implications for Healthcare Professionals and Patients

The gains in Fresenius SE, Siemens Healthineers, and Merck highlight ongoing advancements in medical technology and therapeutics. Clinicians and patients can anticipate:

  • Enhanced treatment options: The approval of Merck’s oncology agent and the deployment of Fresenius’ dialysis platform may improve disease management and patient outcomes.
  • Improved diagnostic capabilities: Siemens Healthineers’ expansion of imaging and laboratory services supports earlier detection and more precise monitoring of chronic conditions.
  • Access to innovation: The continued financial strength of these companies facilitates research and development, potentially accelerating the availability of next‑generation therapies.

Conclusion

The trading session on September 28 2026 reinforced a cautiously optimistic outlook for the German equity market. Fresenius SE and its peers delivered steady gains against a backdrop of solid underlying fundamentals, while sector‑specific volatility moderated the performance of some large-cap names. For healthcare stakeholders, the positive trajectory of Fresenius, Siemens Healthineers, and Merck signals continued progress in medical technology and pharmaceutical innovation, with tangible benefits for patient care and healthcare systems.